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Abstract
In genetic association studies of rare variants, the low power of association tests
is one of the main challenges. In this study, we propose a new single‐marker
association test called C‐JAMP (Copula‐based Joint Analysis of Multiple
Phenotypes), which is based on a joint model of multiple phenotypes given
genetic markers and other covariates. We evaluated its performance and
compared its empirical type I error and power with existing univariate and
multivariate single‐marker and multi‐marker rare‐variant tests in extensive
simulation studies. C‐JAMP yielded unbiased genetic effect estimates and valid
type I errors with an adjusted test statistic. When strongly dependent traits were
jointly analyzed, C‐JAMP had the highest power in all scenarios except when a
high percentage of variants were causal with moderate/small effect sizes. When
traits with weak or moderate dependence were analyzed, whether C‐JAMP or
competing approaches had higher power depended on the effect size. When
C‐JAMP was applied with a misspecified copula function, it still achieved high
power in some of the scenarios considered. In a real‐data application, we
analyzed sequencing data using C‐JAMP and performed the first genome‐wide
association studies of high‐molecular‐weight and medium‐molecular‐weight
adiponectin plasma concentrations. C‐JAMP identified 20 rare variants with p‐
values smaller than 10−5, while all other tests resulted in the identification of
fewer variants with higher p‐values. In summary, the results indicate that C‐
JAMP is a powerful, flexible, and robust method for association studies, and we
identified novel candidate markers for adiponectin. C‐JAMP is implemented as
an R package and freely available from https://cran.r‐project.org/package=
CJAMP.
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1 | INTRODUCTION
Technological advancements and collaborative efforts
have revolutionized the way we study the genetic
underpinnings of complex traits including molecular
and disease phenotypes (Evangelou et al., 2018; PCAWG
Transcriptome Core Group et al., 2018). High‐throughput
sequencing allows now to investigate rare variants in
greater depth, which are abundant and have high
interindividual variability (Telenti et al., 2016), often
unknown phenotypic effects (Schork, Murray, Frazer, &
Topol, 2009), and potentially pivotal roles in diseases
(Mancuso et al., 2016). One of the main challenges in
rare‐variant association studies is the low power of tests,
which limits the identification of novel loci and
contributes to the fact that a large part of the estimated
heritability of most complex traits is still unexplained.
The power can be increased by analyzing larger sample
sizes, optimizing study designs, and using powerful
statistical approaches. The latter is the focus of this study.
In one line of methodological research, multi‐marker
tests (MMTs) have been proposed to increase the power
by aggregating the information of (rare) genetic markers
in a given genomic region and then testing the
association of the region with the trait of interest.
Popular MMTs include burden‐type tests, SKAT (M. C.
Wu et al., 2011), SKAT‐O (Lee, Wu, & Lin, 2012), and
other kernel‐based variance‐component tests (Asimit &
Zeggini, 2010; Lee, Abecasis, Boehnke, & Lin, 2014; Li &
Leal, 2008; Listgarten et al., 2013). While MMTs have
larger power compared to single‐marker tests (SMTs),
which test each genetic marker separately, for the
analysis of binary traits (Asimit & Zeggini, 2010;
Konigorski, Yilmaz, & Pischon, 2017; Lee et al., 2014),
this is not generally the case for the analysis of
quantitative traits. Here, SMTs also have lower power
compared to MMTs when single nucleotide variants
(SNVs) have small effect sizes but equal or larger power
compared to MMTs when SNVs have moderate or large
effect sizes (Konigorski et al., 2017).
Another promising statistical approach to increase the
power of association tests in genome‐wide association
studies (GWAS) is to jointly model multiple traits
(Schillert & Konigorski, 2016), which is intuitive when
different traits of a phenotype are available, such as
different obesity measures or different isoforms of a gene
or protein. Many previously proposed approaches are
based on multivariate generalized linear or linear mixed
models such as MURAT (Sun et al., 2016), aSPU,
aSPUset, aSPUset‐Score (Kim, Zhang, Pan, & Alzheimer’s
Disease Neuroimaging Initiative, 2016; Y. Zhang, Xu,
Shen, Pan, & Alzheimer’s Disease Neuroimaging Initia-
tive, 2014), MultiPhen (O’Reilly et al., 2012), and others
(Kaakinen et al., 2017; Lippert, Casale, Rakitsch, &
Stegle, 2014; Maity, Sullivan, & Tzeng, 2012; Schifano, Li,
Christiani, & Lin, 2013; Wang, Wang, Sha, & Zhang,
2016), or use dimension reduction methods (Aschard
et al., 2014; Yang & Wang, 2012), structural equation
modeling methods (Momen et al., 2018; Song, Morris, &
Stein, 2016; Verhulst, Maes, & Neale, 2017), methods
combining results from univariate analyses (Liang,
Wang, & Zhang, 2016; Liu & Lin, 2018; O’Brien, 1984;
van der Sluis, Posthuma, & Dolan, 2013), or others
(Aschard et al., 2017; Jiang et al., 2015), see the review by
Yang and Wang (2012) for more details. Most of these
approaches assume a very specific and restricted Gaus-
sian dependence structure between traits while there
exist many empirical data sets with non‐Gaussian
dependencies. There exist more recent kernel‐based
approaches including GAMuT (Broadaway, Cutler, &
Duncan, 2016), MSKAT (B. Wu & Pankow, 2016), DKAT
(Zhan et al., 2017), and Multi‐SKAT (Dutta, Scott,
Boehnke, & Lee, 2019) that allow a more flexible
modeling of the multivariate dependence structure. Most
of the above tests are multi‐marker and “multivariate”
tests (i.e., testing the association of all variants in a region
with all traits jointly), hence they may not have optimal
power for testing variants with large effect sizes and
when the tested variants are only associated with a few of
the tested traits. There exist some empirical comparisons
of multivariate tests for the analysis of common (Kim
et al., 2016; Liang et al., 2016; Zhu, Zhang, & Sha, 2015)
and rare genetic variants (Broadaway et al., 2016; Dutta
et al., 2019; B. Wu & Pankow, 2016; Zhan et al., 2017),
however, most comparisons have been limited to a few
selected methods of similar type.
Here, we propose a novel SMT based on joint copula
models of multiple phenotypes and call the approach
C‐JAMP (Copula‐based Joint Analysis of Multiple
Phenotypes). The use of copula functions has been
proposed in some recent GWAS (Dutta et al., 2019; He,
Li, Edmondson, Rader, & Li, 2012; Konigorski, Yilmaz,
& Bull, 2014; Konigorski, Yilmaz, & Pischon, 2016;
Lakhal‐Chaieb, Oualkacha, Richards, & Greenwood,
2016; Ray & Basu, 2017; Rosen & Thompson, 2015; H.
Zhang, Qin, Landi, Caporaso, & Yu, 2013; Zhao &
Zhang, 2016), however, only for the analysis of common
variants or with a different focus than to increase the
power through a test based on the modeling of the
dependence of multiple phenotypes. To our knowledge,
the only previous application of testing rare‐variant
effects in the marginals of joint copula models is in our
pilot study in Konigorski et al. (2016) and further, there
is no available efficient and robust implementation of
association tests in joint copula models for genome‐wide
analyses. The general goal of C‐JAMP is to jointly model
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two (or more) traits conditional on a genetic marker of
interest using copula functions, in order to estimate and
test the association of the marker with either trait.
Copula functions are used to construct a joint distribu-
tion function of multiple traits by combining the
marginal distributions of traits with a dependence
structure. They provide a very flexible tool to model
different multivariate distributions with appropriate
marginal distributions, and we hypothesize that they
allow increasing the power of association tests.
After describing C‐JAMP in more detail in the next
section, we assess its finite‐sample properties as a SMT in
extensive rare‐variant simulation studies of quantitative
traits, and compare its performance to a standard
univariate SMT (i.e., SMT under the univariate model
of a single trait; linear regression), univariate MMTs (a
burden test, SKAT, and SKAT‐O), multivariate SMTs
(MultiPhen, aSPU), as well as to multivariate MMTs
(MURAT, aSPUset, aSPUset‐Score, MSKAT, GAMuT,
and DKAT). Finally, we apply C‐JAMP in a substudy of
the large European Prospective Investigation into Cancer
and Nutrition (EPIC) Potsdam cohort study (Boeing,
Wahrendorf, & Becker, 1999; Riboli & Kaaks, 1997) with
200 probands, and perform—to our knowledge—the first
GWAS of high‐molecular‐weight (HMW) and medium‐
molecular‐weight (MMW) adiponectin plasma concen-
trations, which are different biologically active isoforms
of the hormone adiponectin and have been associated
with obesity and a number of chronic diseases (Aleksan-
drova et al., 2012; Pischon, 2009). An R package with the
implementation of C‐JAMP is freely available from
https://cran.r‐project.org/package=CJAMP.
2 | METHODS
2.1 | C‐JAMP
In C‐JAMP, we propose to jointly model two (or more)
quantitative traits, Y1 and Y2, using copula functions. For
Y Y,1 2, and a covariate vector Z , the joint distribution F of
Y1 and Y2, conditional on Z= z, can be constructed by
combining the marginal distributions of Y1 and Y2, F1 and
F2, conditional on Z= z, using a copula function Cψ with
a parameter vector ψ modeling the dependence structure
between zY |1 and zY |2 :
z z zF y y C F y F y( , ) = ( ( ), ( )).ψ1 2 1 1 2 2 (1)
The copula model allows marginal distributions to
come from any family of distributions, and also to differ
between phenotypes. In the following, we illustrate
C‐JAMP for a covariate vector Z X X G= ( , , )T1 2 including
two nongenetic covariates X1, X2, and one genetic marker
g, and the marginal models
Y γ γ x γ x β g ε= + + + + ,1 0 1 1 2 2 (2)
Y γ γ x γ x β g ε= + + + + ,′ ′ ′ ′ ′2 0 1 1 2 2 (3)
with normally distributed errors ε N σ~ (0, )12 and
ε N σ~ (0, )′ 22 . The dependence parameters in ψ do not
appear in the marginal distributions which allows to
estimate the effect of a SNV G on Y1 or Y2, while
considering the dependence between Y1 and Y2 adjusted
for Z .
Popular copula functions include the Clayton family
(Clayton, 1978)
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with φ > 0, which is illustrated in Figure 1, and the
Gumbel‐Hougaard family (Gumbel, 1960)
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with θ > 1. A third family which includes both (4) and
(5) for θ = 1 and →φ 0, respectively, is the 2‐parameter
copula family
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with ≤ ≤u u0 , 1,1 2 and the copula parameter vector
≥ψ φ θ φ θ= ( , ) , > 0, 1T , which allows to model both
the lower‐ and upper‐tail dependence (Joe, 1997) and
hence a flexible modeling of a large class of dependence
structures. There is a one‐to‐one relation between the
overall dependence measure Kendall’s tau and the copula
parameter vector φ θ( , )T in the model (6); that is
τ θ φ= 1 − 2/( ( + 2))φ θ, . A stronger dependence in the
tails of the distribution can often be found in real data,
see for example the application described in this study.
Focusing on fully parametric models, maxi-
mum likelihood estimates of the parameters
φ θ γ γ γ β γ γ γ β σ σ( , , , , , , , , , , , )′ ′ ′ ′ T0 1 2 0 1 2 1 2 are obtained by
maximizing the likelihood function of the data using
the quasi‐Newton, variable metric BFGS (Broyden‐
Fletcher‐Goldfarb‐Shanno) method (Gentle, 2009).
Standard error estimates of the parameter estimates
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are obtained from the inverse of the observed
information matrix. To identify SNVs associated with
Y1 or Y2 using C‐JAMP, we conduct SMTs and test the
null hypotheses H β: = 00 (vs. ≠H β: 0A ) and
H β: = 0′0 (vs. ≠H β: 0′A ) for each SNV G, respec-
tively, by using the Wald test statistics (Konigorski
et al., 2017). For more statistical and computational
details, see the Supporting Information Note 1 and the
R package documentation at https://cran.r‐project.
org/web/packages/CJAMP/.
Preliminary empirical investigations of C‐JAMP
showed that the asymptotic distribution assumption for
the Wald test statistic may not hold when testing the
association of SNVs that have very few minor alleles
FIGURE 1 Scatterplots of bivariate data (Y1 and Y2) under the Clayton copula. Y1 and Y2 have standard normal marginal distributions
and their dependence was set to Kendall’s τ= 0.2, 0.5, and 0.8. The data was generated using the generate_clayton_copula() function in the
CJAMP R package using the relation φ τ τ= 2 /(1 − ) between Kendall’s τ and the Clayton copula parameter φ, see the vignette of the CJAMP
R package for further details. The Clayton copula allows modeling of the lower‐tail dependence, while the Gumbel copula could be used to
model upper‐tail dependence and the 2‐parameter copula in (6) could be used to model both tail dependencies
Box 1 Algorithm to obtain adjusted Wald test statistics. This algorithm was used to obtain adjusted
Wald test statistics for our simulation study in the following in the scenarios with τ = 0.5 and 0.8. We
considered k = 251 single nucleotide variants (SNVs) with minor allele count (MAC) between 1 and
958 (which equal to MAFs of 0.0005, 0.001, 0.0015, …, 0.4790, respectively), which were observed in the
genetic data used in the simulation study in the main analysis, m = 1,000, for n = 1,000 individuals.
We generated data from the Clayton copula in Step 2 using the generate_clayton_copula() function in
the CJAMP R package and the relationship τ φ φ= /( + 2) between Kendall’s τ and the Clayton copula
parameter φ. In Step 3, the copula model was fitted using the cjamp() function in the CJAMP R
package.
1. Generate data with n observations of k SNVs, for each of the MAC of the SNVs present in the data that will
be analyzed.
Do the following for each of the k SNVs:
2. Generate m sets of phenotypes Y1 and Y2, of size n from the bivariate distribution of interest under the null
hypothesis.
3. Fit the copula model separately for each set of traits conditional on the SNV and obtain the standard Wald
test statisticW for testing the association of the SNV with the trait of interest.
4. Generate m standard normal quantiles Z .
5. Fit a linear regression model of the sorted Z and sortedW , Z α βW ε= + + , and obtain estimates αˆ and βˆ.
In the data analysis, for each of the k SNVs, compute Wald test statisticsW and use the estimates αˆ and βˆ to
obtain adjusted Wald test statisticsWadj asW α βW= ˆ +adj  .
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(with minor allele count [MAC] = 1, 2, or 4) with traits of
moderate/high dependence in a finite‐sample setting
(see Supporting Information Note 2, Tables S1–S3, and
Figure S1). As a consequence, we obtained adjusted Wald
test statistics for traits with dependence ≥τ 0.5 based on
a Monte Carlo simulation study, which is outlined in
Box 1 and described in more detail with a generalization
in Supporting Information Note 2, Table S4, and
Figures S2–S5. These adjusted Wald test statistics were
used for all analyses in the simulation study that are
reported in the following.
2.2 | Simulation study
2.2.1 | Overview
In the simulation study, our aim was to evaluate the
empirical type I error and power of C‐JAMP as a SMT
under a joint model of multiple traits, and to compare its
performance with a standard univariate SMT (linear
regression), univariate MMTs (a burden test, SKAT, and
SKAT‐O), multivariate SMTs (MultiPhen and aSPU), as
well as to multivariate MMTs (MURAT, aSPUset,
aSPUset‐Score, MSKAT, GAMuT, and DKAT) for the
analysis of rare variants. All approaches were evaluated
in their power to identify a causal gene, which amounts
to testing whether any of the SNVs in the gene has an
effect on the trait for SMTs, using a multiple testing
correction for all SNVs in the gene. It has to be noted that
the univariate and multivariate tests were compared in
testing different hypotheses (association with Y1
[H β: = 00 ] with C‐JAMP vs. association with all traits
[H β β: = ′ = 00 ] in multivariate tests) which constitutes
an advantage for the multivariate tests as we primarily
analyzed data generated with effects on both traits. In
addition, we considered scenarios where the genetic
effects on the second trait are smaller or absent. Our
primary focus was on the analysis of non‐Gaussian
dependencies between traits, which often occur in
empirical datasets, but we also considered phenotypes
that follow a bivariate normal distribution.
2.2.2 | Genetic data generation and
general study set‐up
The set‐up of the simulation study is described in detail
in the Supporting Information Note 3. In brief, we used
the genetic data set provided in the SKAT package in R to
obtainm = 10,000 genes as replicates with on average 58
SNVs (min = 36; max = 81 SNVs). The sample size was
set to n= 1,000. Two traits, Y1 and Y2, were generated
from the 1‐parameter Clayton copula model in (4)
conditional on two covariates x1 and x2 (and conditional
on the causal SNVs gj under the alternative hypotheses
with additive genetic effects). We considered weak
(Kendall’s tau, τ = 0.2), moderate (τ = 0.5) and strong
(τ = 0.8) dependence levels under the Clayton copula
model. Using the one‐to‐one relation τ φ φ= /( + 2)
between Kendall’s τ and the Clayton copula parameter
φ, the corresponding copula parameter values are
obtained from φ τ τ= 2 /(1 − ). The marginal models of
the two traits were considered as
∑Y x x β g ε= 0.5 + 0.5 + + ,j j1 1 2 (7)
∑Y x x β g ε= 0.5 + 0.5 + + ,′ ′j j2 1 2 (8)
where X Bin X N ε ε N~ (0.5), ~ (0, 1), , ′~ (0, 1)1 2 , β c log= |j Y 101
(MAF)|j , β c log= | (MAF)|′j Y j102 , with different values for
c candY Y1 2 and different percentages of causal variants
(see Table 1; Konigorski et al., 2017; Lee et al., 2012). In
each scenario, genetic effects were all in the same
direction. This allowed evaluating C‐JAMP when MMTs
are more powerful (Konigorski et al., 2017; Lee et al.,
2012). For Scenarios 0–12, for C‐JAMP, all results
regarding type I error and power estimates were similar
for the two traits Y1 and Y2, and are reported only for
testing the association with Y1. Scenarios 13–15 were
analyzed for C‐JAMP to evaluate its type I error with
respect to one trait (here: Y2) when the SNVs are only
associated with the other trait (Y1). Also, Scenarios 13–17
were analyzed to investigate the power of C‐JAMP,
MURAT, aSPUset, aSPUset‐Score, MSKAT, GAMuT, and
DKAT when there is no or only a smaller genetic effect
on the second trait Y2. Here, the power of C‐JAMP was
reported with respect to testing the association with Y1. In
the evaluation, we did not assess the power of MultiPhen
and aSPU since they did not yield valid empirical
type I errors under the assumed model. To investigate
scenarios with bivariate normally distributed phenotypes,
Y1 and Y2 were generated using the same marginal
models in (7) and (8) but with a bivariate Gaussian
dependence structure (see Supporting Information Note 3
for details).
2.2.3 | Investigated rare variant tests
To evaluate the performance of C‐JAMP, joint models of
the generated phenotypes Y1 and Y2 given the SNV g and
covariates X X,1 2 were fitted using the Clayton copula in
(4) with the marginal models in (2)–(3) using the cjamp()
function in the R package CJAMP. Initially, we also fitted
the 2‐parameter copula family as a check and obtained
the same results (data not shown), since the two‐
parameter copula family includes the Clayton model.
Hence, for data generated from the Clayton copula, we
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fitted C‐JAMP based on the Clayton copula model since it
is computationally faster. The unadjusted Wald test
statistic was used for since it already has valid type I
error, and adjusted Wald test statistics were computed for
τ = 0.5 and 0.8 due to the deflated and inflated type I
errors for some nominal values. In the analysis of
bivariate normally distributed phenotypes, C‐JAMP was
evaluated by fitting the (misspecified) 2‐parameter copula
without adjustment of the Wald test statistic. For
evaluation of the existing methods, their available
implementations in R were used. In short, the lm()
function was used to fit linear regression models and to
obtain SMT p‐values, and the p.adjust() function was
used to obtain the Benjamini‐Hochberg (BH; Benjamini
& Hochberg, 1995) corrected SMT p‐values. Both SKAT
and SKAT‐O were computed using the default linear‐
weighted kernel in the test statistics as it returned the
highest power estimates among all possible options
provided in the SKAT() function in the SKAT package
in R. The burden test was conducted under a linear
regression model of each trait separately by using the
sum of the minor alleles of all rare SNVs in the gene as
predictor. MURAT is a multivariate generalization of the
multi‐marker SKAT and a data‐adaptive variance‐com-
ponent test for the overall effect of all SNVs on all traits.
It was computed using the MURAT() function in the
MURAT R package with default settings. MultiPhen uses
proportional odds logistic regression to predict each
genotype by the multiple phenotypes and was computed
using the mPhen() function in the MultiPhen R package
with default settings, which tests the association of each
SNV with each trait separately, as well as the association
of each SNV with all traits. aSPU, aSPUset, and aSPUset‐
Score are data‐adaptive powered score tests based on
a multivariate marginal linear model of the traits
conditional on one SNV (aSPU) or multiple SNVs
(aSPUset and aSPUset‐Score). aSPU was computed using
the GEEaSPU() function in the GEEaSPU R package with
default setting and evaluated for testing all SNVs within a
gene to yield gene‐level p‐values. aSPUset and aSPUset‐
Score are multivariate gene‐level association tests of the
absence of effects of all SNVs on all traits and were
performed using the GEEaSPUset() function in the
GEEaSPU R package with default settings. Similar to
MURAT, MSKAT is a multivariate extension of SKAT
assuming a linear model between each trait and all SNVs,
and constructs a score‐based test statistic associating all
SNVs in a gene with all traits. We used the MSKAT()
function in the MSKAT package with default settings.
GAMuT uses two kernels to model the similarities
between phenotypes and between SNVs and constructs
a test statistic based on the kernel distance covariance.
We applied GAMuT by using the TestGAMuT() function
with default settings. Finally, DKAT uses the dual‐kernel
framework similar to GAMuT but constructs a different
test statistic for comparing the phenotype and SNV
kernels, and we used the DKAT() function with default
settings. See Supporting Information Note 4 for details.
TABLE 1 Overview of the simulation study scenarios
Investigation Scenario
% of causal
variants Effect sizes
Median (MAD) of
explained variance in %
Type I error 0 0% c c= = 0Y Y1 2 –
1 5% c c= = 0.6Y Y1 2 0.9% (0.6)
2 5% c c= = 0.3Y Y1 2 0.2% (0.2)
3 5% c c= = 0.2Y Y1 2 0.1% (0.1)
4 10% c c= = 0.6Y Y1 2 1.9% (1.4)
5 10% c c= = 0.3Y Y1 2 0.5% (0.3)
Power 6 10% c c= = 0.2Y Y1 2 0.2% (0.2)
7 20% c c= = 0.6Y Y1 2 3.8% (2.1)
8 20% c c= = 0.3Y Y1 2 1.0% (0.6)
9 20% c c= = 0.2Y Y1 2 0.4% (0.2)
10 50% c c= = 0.6Y Y1 2 9.1% (3.0)
11 50% c c= = 0.3Y Y1 2 2.4% (0.9)
12 50% c c= = 0.2Y Y1 2 1.1% (0.4)
13 10% c ; c= 0.6 = 0Y Y1 2 As in Scenario 4
Additional investigations
of type I error and power
14 20% c ; c= 0.3 = 0Y Y1 2 As in Scenario 8
15 50% c ; c= 0.2 = 0Y Y1 2 As in Scenario 12
16 10% c ; c= 0.6 = 0.1Y Y1 2 As in Scenario 4
17 10% c ; c= 0.6 = 0Y Y1 2 .2 As in Scenarios 1 and 3
Note: The 17 scenarios vary the percentage of causal variants and their effect sizes to investigate the empirical type I error and power. The percentage of causal
rare variants is with respect to the total number of rare variants with MAF≤ 0.03 in the gene. The effect size β of a SNV with a given MAF on the first trait Y1 is
c log· | (MAF)|Y 101 , and on the second trait Y2 is c log· | (MAF)|Y 102 . The percentage of explained variance for a given gene is calculated as the sum of
β Y2·MAF ·(1 − MAF)· /Var( )i i i2 over all variants i in the gene.
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2.3 | Analysis of adiponectin levels
For an application of C‐JAMP, a GWAS of rare SNVs with
HMW and MMW adiponectin concentrations was per-
formed. Adiponectin is a hormone predominantly synthe-
sized and secreted by adipocytes in the adipose tissue. It is
involved, among others, in the regulation of insulin
sensitivity and energy homeostasis. It increases insulin
sensitivity, decreases inflammation, and is inversely
associated with obesity, risk of type 2 diabetes, coronary
heart disease, and several types of cancer (Aleksandrova
et al., 2012; Pischon, 2009). Adiponectin circulates in
different molecular fractions, which differ in their meta-
bolic roles and involvement in molecular processes
(Pischon, 2009), yet they are correlated, so including their
information in joint modeling of the different fractions is
an intuitive way to increase the power of association tests.
The data stems from a substudy of n=200 probands
within the large EPIC Potsdam study (Konigorski et al.,
2018). 2,109,385 SNVs were called from RNA‐Seq experi-
ments and after stringent quality control checks, 176,733
biallelic autosomal rare SNVs in 23,922 genes with MAF≤
0.03 were included in the analysis, excluding singletons
with MAF= 0.0027. C‐JAMP was applied as an SMT by
estimating the association of each SNV separately with each
adiponectin fraction, and performing both variant‐level and
gene‐level tests for each gene assessing whether any of the
SNVs in the gene (within 5 kb of the gene boundary) shows
an association with either adiponectin fraction. In addition,
SMT under a univariate linear regression model and
SKAT‐O, MURAT, MSKAT, and DKAT as MMTs were
computed. In all approaches, age, sex, physical activity,
education, and BMI were incorporated into the models as
covariates, and a complete data analysis was performed
yielding a sample size of n=188. For further details, see
Supporting Information Note 5.
3 | RESULTS
3.1 | Empirical type I error rates of
C‐JAMP and other approaches
First, we report empirical type I errors of C‐JAMP and the
competing approaches for testing the null hypothesis that
the gene is not associated with the trait. We provide results
for both the data generated from the Clayton copula and
from the bivariate normal distribution (Table 2).
The empirical type I error of C‐JAMP was generally
close to the nominal level under each dependence level
and multivariate distribution considered. The univariate
SMT based on linear regression and the three univariate
MMTs all had valid empirical type I errors. Similarly,
MURAT, aSPUset, aSPUset‐Score, MSKAT, GAMuT, and T
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DKAT had empirical type I errors close to the nominal
level, but some of them showed a slight inflation in the
analysis of traits with high dependence. The aSPU test and
the MultiPhen joint test of all traits led to inflated or highly
inflated type I errors—for example, the type I error of the
MultiPhen test was six times as high as the nominal level.
The MultiPhen test of the genetic association with one
trait, on the other hand, provided highly deflated type I
errors and was also not valid. Consequently, the aSPU and
MultiPhen tests were not included in the power study.
The empirical type I errors of C‐JAMP were also close
to the nominal levels for smaller levels (α = 10 ,−2
10 , 10 , 10−3 −4 −5; see Table S5), but slightly larger in a
few scenarios for some of the smaller nominal levels.
They can be further controlled if the analysis is restricted
to SNVs with MAC> 2 or MAC> 4, that is removing
singletons and doubletons from the analysis (Table S6).
The Bonferroni correction provided empirical levels
closer to the nominal levels compared to the BH
correction (Table S5) and was, therefore, used in the
power evaluation in the next section. Further investiga-
tions of C‐JAMP confirmed that the empirical type I
errors were also well‐calibrated when evaluated on a
SNV‐level instead of the gene‐level (Table S7). In the
scenario that SNVs were only affecting one of the two
traits in the joint model, the empirical type I errors were
valid when there was a weak or moderate dependence
between the traits. If the traits had a strong dependence,
however, then the type I errors were inflated (Table S8).
See Supporting Information Note 6 for further details.
3.2 | Empirical power of C‐JAMP
compared with other approaches
The results of the power comparisons are shown in Figure
2, comparing C‐JAMP with the univariate SMT and
MMTs, and in Figure 3, comparing C‐JAMP with the
multivariate MMTs, under the Scenarios 1–12 described in
FIGURE 2 Empirical power estimates of C‐JAMP and the univariate single‐marker test (SMT) and multi‐marker tests. Data was
generated under an alternative‐hypothesis model described in Scenarios 1–12 in Table 1 for n = 1,000 individuals with m = 10,000
replicates. The nominal α was set to 0.05 and 2.5 × 10−6. Adjustments for multiple testing of all single nucleotide variants in a gene with
C‐JAMP were done using the Bonferroni correction and for testing with SMT using the BH‐correction. Power estimates are shown for
testing the association with the first trait Y1.
KONIGORSKI ET AL. | 33
Table 1, when the nominal type I errors were 0.05 or
2.5 × 10−6 (which would be the Bonferroni‐corrected
threshold for the analysis of 20,000 genes in applications)
and data was generated from the Clayton copula (see
Tables S9–S10 for more details).
As a first observation, the power of C‐JAMP increased
with increasing dependence between the traits (Figure 2).
This was in contrast to all other investigated multivariate
approaches, whose power was inversely affected by the
dependence between traits: if the dependence between
traits increased, their power decreased (Figure 3).
Second, in comparison to the SMT based on a univariate
model of a trait, C‐JAMP led to consistently higher
power, and the power gain was larger when there was a
higher dependence between the two traits. Third, the
burden test and aSPUset had the lowest power across
all scenarios, and always had smaller power compared to
C‐JAMP. Fourth, regarding the multivariate tests,
MSKAT and GAMuT had identical power up to three
decimals and had lower power compared to DKAT in
almost all scenarios. DKAT and MURAT had often
similar power and in some scenarios DKAT had higher
power, in other scenarios MURAT had higher power.
Fifth, in a comparison of C‐JAMP with all competing
approaches, C‐JAMP had the highest power in all
scenarios when traits with high dependence were
analyzed, except when 50% of variants were causal and
all had moderate/small effect sizes (Scenarios 11 and 12),
where SKAT‐O or DKAT had slightly higher power.
When traits with weak or moderate dependence were
analyzed, whether C‐JAMP or competing approaches had
the highest power depended on the effect size and the
FIGURE 3 Empirical power estimates of C‐JAMP and the multivariate multi‐marker tests. Data was generated under an alternative‐
hypothesis model described in Scenarios 1–12 in Table 1 for n = 1,000 individuals with m = 10,000 replicates, and under different
dependence levels between the two traits Y1 and Y2 (Kendall’s τ = 0.2, 0.5, and 0.8). The nominal α was set to 0.05. Adjustments for multiple
testing of all single nucleotide variants in a gene with C‐JAMP were done using the Bonferroni‐correction. Power estimates are shown for
testing the association with the first trait Y1 for C‐JAMP and for testing the association with both traits with aSPUset, aSPUset‐Score,
MURAT, MSKAT, GAMuT, and DKAT. Since the power of MSKAT and GAMuT was identical up to three decimals in all scenarios, they are
shown together in the figure.
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percentage of causal variants. In this case, C‐JAMP still
had the highest power compared to all competing
approaches when effect sizes were high (Scenarios 1, 4,
7, and 10). When effect sizes were moderate (Scenarios 2,
5, 8, and 11), C‐JAMP had similar power compared to
SKAT, SKAT‐O, MURAT, aSPUset‐Score, MSKAT, and
GAMuT if 5%, 10%, or 20% SNVs in a gene were causal
(Scenarios 2, 5, and 8), and lower power if 50% SNVs in a
gene was causal (Scenario 11). Finally, when effect sizes
were small (Scenarios 3, 6, 9, and 12), C‐JAMP had
similar power for 5% or 10% causal SNVs and smaller
power for 20% and 50% causal SNVs in a gene.
In the first sensitivity checks, the power of C‐JAMP
was investigated when SNVs with MAC≤ 2 or with
MAC≤ 4 were removed from the analysis (Table S11) to
control the type I error more stringently for small
nominal values (i.e., α = 2.5 × 10−6). The results inter-
estingly showed that the power of C‐JAMP was
consistently higher compared to the analyses where all
SNVs in a gene were included. This was even more
apparent for low‐powered scenarios.
Second, when bivariate normally distributed traits were
analyzed by applying C‐JAMP with a misspecified copula
function (Table S12), C‐JAMP still had the highest power
in scenarios with large genetic effect sizes (Scenario 1) for
every trait dependence level—in Scenario 10, all ap-
proaches except aSPUset had a power of 1. When there
were 5% causal SNVs with moderate or weak effect sizes
(Scenarios 2 and 3), C‐JAMP had similar power to
MURAT, MSKAT, GAMuT and DKAT for every trait
dependence level except for Scenario 3 and weak
dependence, where C‐JAMP had lower power. Finally,
for 50% causal SNVs with moderate or weak effect sizes
(Scenarios 11, 12), C‐JAMP had consistently lower power
compared to MSKAT, GAMuT, and DKAT for every trait
dependence level, and partly also compared to MURAT.
In further sensitivity checks, if the genetic effects were
only affecting the first trait and were absent on the second
trait (Scenarios 13–17), then the power of C‐JAMP was not
affected and did not decrease (see Table S13). The power
of aSPUset, aSPUset‐Score, MURAT, MSKAT, GAMuT,
and DKAT, however, decreased markedly when the
genetic effect was absent or smaller on the second trait.
3.3 | Analysis of adiponectin levels
For the analysis of adiponectin traits, Table S14 shows
descriptive characteristics of the study population, and
Figure S6 shows a scatterplot of HMW and MMW
adiponectin, indicating that the 2‐parameter copula was
appropriate to model their bivariate distribution with higher
upper‐tail dependence. In support, we note that the Akaike
information criterion (AIC) value under the 2‐parameter
copula model in (6) with the marginal models (2) and (3)
was much lower than the AIC under a bivariate normal
model, indicating that the copula model was a better fit. For
example, the AIC value under the copula model conditioning
on nongenetic covariates without conditioning on a parti-
cular SNV was 572.4 compared to an AIC value of 633.7
under a bivariate normal model with the samemarginals. An
inspection of quantile–quantile (Q–Q) plots of the p‐values
did not indicate a substantial inflation for variant‐level tests
using C‐JAMP and SMT under univariate linear regression,
or of gene‐based tests using C‐JAMP, the SMT under linear
regression, SKAT‐O, MURAT, MSKAT, or DKAT.
In the analysis using C‐JAMP, in variant‐level analyses,
while none of the SNVs reached genome‐wide significance
with p‐value < 5 × 10−8, C‐JAMP identified 11 SNVs for
HMW adiponectin and nine SNVs for MMW adiponectin
with p‐value < 10−5, of which 7 (for HMW) and 0 (for
MMW) had BH‐adjusted p‐value < 0.05, respectively.
Gene‐level analyses supported the results of the variant‐
level analyses and identified six genes for HMW adipo-
nectin and one gene for MMW adiponectin with
p‐value < 10−5, and 10 genes (for HMW) as well as no
gene (for MMW) with BH‐adjusted p‐value < 0.05, respec-
tively. All except two genes identified in the gene‐level
analyses were also identified in the variant‐level analyses,
while none of the SNVs or genes identified for HMW
adiponectin overlapped with those for MMW adiponectin
(see Tables 3 and 4 for detailed results).
In comparison to C‐JAMP, SMTs based on linear
regression yielded only 8 SNVs for HMW adiponectin and
four SNVs for MMW adiponectin with p‐value < 10−5. All
these SNVs were also identified by C‐JAMP but had higher
p‐values in linear regression (see Table 3). In addition, none
of these SNVs had a BH‐adjusted p‐value < 0.05 and gene‐
level tests also did not yield any gene with p‐value< 10−5
(Table 4). Gene‐level tests with SKAT‐O, MURAT, MSKAT,
and DKAT did not yield any gene with p‐value < 10−5 or
BH‐adjusted p‐value< 0.05 (Table 4). The conclusion for
these methods did not change when other kernels were
used or when singletons were included in the analysis. As a
result, they provided higher p‐values compared to C‐JAMP
in the real‐data application.
4 | DISCUSSION
In this study, we introduce a novel rare‐variant association
test based on a joint copula model of multiple phenotypes
called C‐JAMP, evaluate it in comparison to different
established approaches in extensive simulation studies, and
apply C‐JAMP in an empirical analysis of adiponectin traits.
One of the main advantages of C‐JAMP is that through the
use of copula functions, many different dependence
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structures between traits can be modeled. Model selection
approaches and goodness of fit tests (see Yilmaz, 2009, for a
review) can be used to obtain a plausible copula model for
the joint distribution of the considered traits in a given
application. The 2‐parameter copula function used in this
study encompasses a wide range of dependencies, and as an
Archimedean copula also encompasses random effect
models (Joe, 1997). In addition, C‐JAMP provides the
flexibility to use different genetic models for the effect of
each SNV, to use any marginal distribution of a given trait
conditional on the SNV and other factors, to model other
trait types such as time‐to‐event traits, and to jointly model
traits of family members. As one of the challenges that was
revealed in preliminary investigations, the large sample
Wald test statistic in copula models needs an adjustment for
the analysis of moderate or strong trait dependences and
SNVs with very low frequency to avoid inflated type I
errors. Here, we presented an empirical adjustment of the
Wald test statistic, which yielded empirical type I errors
close to the nominal levels. The restriction to analyze only
SNVs with at least 2 or 4 copies of the minor allele can
provide additional control of the type I error, which is
important for real‐data analyses.
Based on these adjusted Wald test statistics, our results
indicate that the power of association tests can be increased
through the joint modeling of multiple traits using
C‐JAMP. The power of C‐JAMP increased when the traits
had higher dependence—contrary to the performance of
all competing multivariate approaches—and in some of the
considered scenarios, the power of C‐JAMP was 1.5× or 2×
as high as the best competitor. More specifically, when
traits with high dependence were analyzed, C‐JAMP
outperformed all competitors in all scenarios except when
50% of variants were causal and all had moderate/small
effect sizes. When traits with weak or moderate depen-
dence were analyzed, whether C‐JAMP or competing
approaches had the highest power depended on the effect
size. SKAT‐O, MURAT, MSKAT, GAMuT, and DKAT had
the highest power gain compared to C‐JAMP when traits
were weakly dependent and many variants in a gene were
causal but all had small effects sizes. Regarding the other
investigated tests, aSPU and MultiPhen yielded invalid
inference for the analysis of rare variants under the
considered models, and the standard SMT, burden test and
aSPUset always had less power compared to C‐JAMP. In
the simulation study, we also investigated C‐JAMP when
the multivariate distribution was misspecified and obtained
similar results in the type I error evaluation and power
comparison, except when there were a large number of
causal SNVs with moderate or weak effect sizes then
MSKAT, GAMuT, and DKAT had consistently higher
power. These results indicated that C‐JAMP with the
TABLE 3 Results from variant‐level association analyses of adiponectin traits
C‐JAMP SMT
rsID chr Position Gene MAF p‐value adj. p‐value p‐value adj. p‐value
HMW adiponectin
– 17 35,097,367 RAD51D 0.011 3.2 × 10−7 0.02 6.0 × 10−6 0.17
rs11746883 5 151,676,482 SPARC 0.019 3.3 × 10−7 0.02 2.7 × 10−6 0.17
rs1029303 13 32,439,013 N4BP2L2 0.008 3.4 × 10−7 0.02 4.1 × 10−6 0.17
rs188769218 2 88,886,106 – 0.011 3.6 × 10−7 0.02 6.7 × 10−7 0.12
– 2 109,819,508 RGPD5 0.005 1.1 × 10−6 0.03 7.7 × 10−6 0.17
– 8 100,709,384 PABPC1 0.005 1.1 × 10−6 0.03 7.7 × 10−6 0.17
rs149200056 17 34,962,071 CCT6B, ZNF830 0.005 1.1 × 10−6 0.03 7.7 × 10−6 0.17
– 19 38,408,438 FAM98C 0.021 2.9 × 10−6 0.06 5.9 × 10−6 0.17
rs17055869 8 26,740,131 – 0.021 3.2 × 10−6 0.06 1.7 × 10−5 0.33
rs144213212 9 128,356,275 SLC27A4 0.019 3.9 × 10−6 0.07 2.7 × 10−5 0.48
rs75975249 15 74,513,902 – 0.013 9.8 × 10−6 0.10 5.1 × 10−5 0.54
MMW adiponectin
rs36043647 2 201,277,115 CASP8 0.021 1.0 × 10−6 0.07 4.8 × 10−6 0.28
rs1367710075 15 32,185,288 – 0.011 1.2 × 10−6 0.07 7.5 × 10−6 0.33
rs74092385 14 105,463,408 MTA1 0.016 1.3 × 10−6 0.07 2.1 × 10−6 0.28
rs10513865 3 191,371,096 CCDC50 0.021 1.6 × 10−6 0.07 4.7 × 10−6 0.28
rs55656828 5 151,447,743 SLC36A1 0.013 2.8 × 10−6 0.10 1.6 × 10−5 0.41
rs113408613 12 112,912,550 OAS1 0.005 6.9 × 10−6 0.15 2.8 × 10−5 0.45
– 3 142,827,996 PCOLCE2 0.005 6.9 × 10−6 0.15 2.8 × 10−5 0.45
– 15 98,923,881 IGF1R 0.005 6.9 × 10−6 0.15 2.8 × 10−5 0.45
rs56213419 8 143,694,737 ZNF707,
LOC101928160
0.008 9.8 × 10−6 0.17 2.3 × 10−5 0.45
Note: Shown are SNVs with p‐values < 10‐5 in variant‐level tests using C‐JAMP, for HMW (upper panel) and MMW adiponectin (lower panel), and the respective
p‐values from variant‐level tests using linear regression. Shown are the rs SNP ID, chromosome, position, gene symbol, minor allele frequency (MAF), unadjusted
p‐values (“p‐value”) and BH‐adjusted p‐values (“adj. p‐value”) of C‐JAMP and linear regression (“SMT”).
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assumed 2‐parameter copula model is robust against
misspecification of the dependence structure, and we
recommend using this more general copula model in
practical applications. Nonetheless, it is always important
to assess the plausibility of the chosen copula function first
in real data analyses and to use a plausible model.
A general downside of MMTs is that they rely on multiple
assumptions (e.g., many SNVs in a gene are causal) and
parameters (e.g., the choice of power sets), and even an
integration of many different subtests does not always yield
tests with optimal power, as shown by the results of the
simulation studies. On the other hand, SMTs rely on much
fewer assumptions. For example, since we investigated the
situation where MMTs have optimal power (all causal
variants have an effect in the same direction), the power of
C‐JAMP can be expected to compare even more favorably to
MMTs when effects are not all in the same direction, since
the power of C‐JAMP as an SMT is not affected by this
(Konigorski et al., 2017). Further, it should be noted that in
the simulation study, the data was generated from the same
model as in Lee et al. (2012) where the effect size of each
SNV depends on the MAF of the corresponding SNV
through a specified function (see Table 1). Since the weighted
kernel functions in SKAT, SKAT‐O, MURAT, MSKAT,
GAMuT, and DKAT use weights dependent on the MAF of
SNVs, this gives them an advantage and allowed us to
evaluate C‐JAMP in situations where these MMTs have
optimal power. In addition, while multi‐degree‐of‐freedom
tests generally have the highest power when a genetic variant
affects all tested traits, they provide less or no information on
which traits are associated, and they lose power when only
one or a few traits are associated. Therefore, in real
applications, the power of C‐JAMP might compare even
more favorably to these MMTs.
Regarding the computational cost, C‐JAMP is compu-
tationally intensive compared to standard regression
approaches and the kernel‐based tests due to the
optimization of a more complex likelihood function, but
still fast enough to be employed on a genome‐wide scale.
For example, the real‐data association analysis of the
23,922 genes with adiponectin levels was computed in
less than 4 hours on a cluster with 200 compute nodes (cf.
Figure S7 for more general run times). In this regard, it
would be interesting in future studies to investigate
algorithmic improvements of C‐JAMP to be computa-
tionally more efficient and scale to high‐dimensional
traits. Some competing tests such as the aSPUset and
aSPUset‐Score tests are computationally more intensive
and not suitable for genome‐wide analyses, where
evidence in form of p‐values smaller than 10−5 or 10−8
is needed. That is, since permutation or simulation
approaches are employed to derive p‐values
of aSPUset and aSPUset‐Score empirically, 10k
permutations are needed to be able to obtain p‐values
that are potentially as small as (10 + 1)k −1.
The results from the data application to adiponectin
levels supported the results from the simulation study
that C‐JAMP is a powerful approach for rare‐variant
analyses and can outperform competing approaches and
yielded 20 SNVs with p‐values <10−5. While the data
application was limited to SNVs in coding regions of
genes that are expressed in adipose tissue and limited by
the sample size, it constitutes the first GWAS of rare
SNVs with high‐ and medium‐molecular‐weight adipo-
nectin fractions and yielded novel candidate markers for
adiponectin. In our opinion, the most interesting marker
for replication studies is rs11746883 in the SPARC gene,
which has been previously implicated in obesity and
chronic diseases (Kos & Wilding, 2010; Takahashi et al.,
2001). This marker might help to explain the relation
between the SPARC gene and adiponectin and their role
in obesity. This illustrates the potential of applying
appropriate statistical models to analyze the complex
interplay of genetic factors with molecular as well as
nonmolecular phenotypes to investigate more complex
biological models. With the multitude of factors having a
likely role in the development of complex traits
(Solovieff, Cotsapas, Lee, Purcell, & Smoller, 2013), C‐
JAMP provides a powerful tool for association studies
and beyond, for example, to investigate alternative
definitions of pleiotropy (Konigorski et al., 2014).
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